392 related articles for article (PubMed ID: 11575928)
1. Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure.
Lang R; Kocourek A; Braun M; Tschesche H; Huber R; Bode W; Maskos K
J Mol Biol; 2001 Sep; 312(4):731-42. PubMed ID: 11575928
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor.
Nar H; Werle K; Bauer MM; Dollinger H; Jung B
J Mol Biol; 2001 Sep; 312(4):743-51. PubMed ID: 11575929
[TBL] [Abstract][Full Text] [Related]
3. High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor.
Moy FJ; Chanda PK; Chen JM; Cosmi S; Edris W; Levin JI; Powers R
J Mol Biol; 2000 Sep; 302(3):671-89. PubMed ID: 10986126
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor.
Fernandez-Catalan C; Bode W; Huber R; Turk D; Calvete JJ; Lichte A; Tschesche H; Maskos K
EMBO J; 1998 Sep; 17(17):5238-48. PubMed ID: 9724659
[TBL] [Abstract][Full Text] [Related]
5. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.
Kiyama R; Tamura Y; Watanabe F; Tsuzuki H; Ohtani M; Yodo M
J Med Chem; 1999 May; 42(10):1723-38. PubMed ID: 10346925
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y
J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state.
Gall AL; Ruff M; Kannan R; Cuniasse P; Yiotakis A; Dive V; Rio MC; Basset P; Moras D
J Mol Biol; 2001 Mar; 307(2):577-86. PubMed ID: 11254383
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of the stromelysin catalytic domain at 2.0 A resolution: inhibitor-induced conformational changes.
Chen L; Rydel TJ; Gu F; Dunaway CM; Pikul S; Dunham KM; Barnett BL
J Mol Biol; 1999 Oct; 293(3):545-57. PubMed ID: 10543949
[TBL] [Abstract][Full Text] [Related]
9. Understanding the P1' specificity of the matrix metalloproteinases: effect of S1' pocket mutations in matrilysin and stromelysin-1.
Welch AR; Holman CM; Huber M; Brenner MC; Browner MF; Van Wart HE
Biochemistry; 1996 Aug; 35(31):10103-9. PubMed ID: 8756473
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 A resolution.
Tsunemi M; Matsuura Y; Sakakibara S; Katsube Y
Biochemistry; 1996 Sep; 35(36):11570-6. PubMed ID: 8794736
[TBL] [Abstract][Full Text] [Related]
11. Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8).
Pochetti G; Montanari R; Gege C; Chevrier C; Taveras AG; Mazza F
J Med Chem; 2009 Feb; 52(4):1040-9. PubMed ID: 19173605
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of human carboxypeptidase M, a membrane-bound enzyme that regulates peptide hormone activity.
Reverter D; Maskos K; Tan F; Skidgel RA; Bode W
J Mol Biol; 2004 Apr; 338(2):257-69. PubMed ID: 15066430
[TBL] [Abstract][Full Text] [Related]
13. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
Jani M; Tordai H; Trexler M; Bányai L; Patthy L
Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
[TBL] [Abstract][Full Text] [Related]
14. Refined 2.0 A X-ray crystal structure of the snake venom zinc-endopeptidase adamalysin II. Primary and tertiary structure determination, refinement, molecular structure and comparison with astacin, collagenase and thermolysin.
Gomis-Rüth FX; Kress LF; Kellermann J; Mayr I; Lee X; Huber R; Bode W
J Mol Biol; 1994 Jun; 239(4):513-44. PubMed ID: 8006965
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the catalytic domain of MMP-16/MT3-MMP: characterization of MT-MMP specific features.
Lang R; Braun M; Sounni NE; Noel A; Frankenne F; Foidart JM; Bode W; Maskos K
J Mol Biol; 2004 Feb; 336(1):213-25. PubMed ID: 14741217
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of the catalytic domain of human matrix metalloproteinase 10.
Bertini I; Calderone V; Fragai M; Luchinat C; Mangani S; Terni B
J Mol Biol; 2004 Feb; 336(3):707-16. PubMed ID: 15095982
[TBL] [Abstract][Full Text] [Related]
17. X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity.
Pavlovsky AG; Williams MG; Ye QZ; Ortwine DF; Purchase CF; White AD; Dhanaraj V; Roth BD; Johnson LL; Hupe D; Humblet C; Blundell TL
Protein Sci; 1999 Jul; 8(7):1455-62. PubMed ID: 10422833
[TBL] [Abstract][Full Text] [Related]
18. Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding.
Botos I; Scapozza L; Zhang D; Liotta LA; Meyer EF
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2749-54. PubMed ID: 8610113
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for the highly selective inhibition of MMP-13.
Engel CK; Pirard B; Schimanski S; Kirsch R; Habermann J; Klingler O; Schlotte V; Weithmann KU; Wendt KU
Chem Biol; 2005 Feb; 12(2):181-9. PubMed ID: 15734645
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1.
Gomis-Rüth FX; Maskos K; Betz M; Bergner A; Huber R; Suzuki K; Yoshida N; Nagase H; Brew K; Bourenkov GP; Bartunik H; Bode W
Nature; 1997 Sep; 389(6646):77-81. PubMed ID: 9288970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
